These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22791984)

  • 1. Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain.
    Prommer E; Ficek B
    Patient Prefer Adherence; 2012; 6():465-75. PubMed ID: 22791984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
    Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
    Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based treatment of cancer-related breakthrough pain with opioids.
    Zeppetella G
    J Natl Compr Canc Netw; 2013 Mar; 11 Suppl 1():S37-43. PubMed ID: 23520185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
    Überall MA
    MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fentanyl buccal tablet.
    Messina J; Darwish M; Fine PG
    Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
    Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
    Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
    Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
    Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose fentanyl sublingual spray for breakthrough cancer pain.
    Taylor DR
    Clin Pharmacol; 2013; 5():131-41. PubMed ID: 23901300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of breakthrough pain in children with cancer.
    Friedrichsdorf SJ; Postier A
    J Pain Res; 2014; 7():117-23. PubMed ID: 24639603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fentanyl sublingual spray for breakthrough pain in cancer patients.
    Zeppetella G
    Pain Ther; 2013 Jun; 2(1):1-9. PubMed ID: 25135032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients.
    Brząkała J; Leppert W
    Pharmacol Rep; 2019 Jun; 71(3):438-442. PubMed ID: 31003154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
    Mercadante S
    Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new transmucosal drug delivery system for patients with breakthrough cancer pain: the fentanyl effervescent buccal tablet.
    Freye E
    J Pain Res; 2008 Dec; 2():13-20. PubMed ID: 21197291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
    Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
    J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fentanyl buccal tablet: faster rescue analgesia for breakthrough pain?
    Lecybyl R; Hanna M
    Future Oncol; 2007 Aug; 3(4):375-9. PubMed ID: 17661711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.
    Zeppetella G; Davies A; Eijgelshoven I; Jansen JP
    J Pain Symptom Manage; 2014 Apr; 47(4):772-785.e5. PubMed ID: 23981487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
    Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK
    Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.